Drug interactions
Nivolumab + Rozanolixizumab
Severity: Moderate
Nivolumab and Rozanolixizumab: moderate interaction.
Last updated
For healthcare professionals — reference only. This page is a brief summary, not medical advice and not a substitute for official labeling or clinical judgement. Always verify before prescribing or dispensing.
Summary
Rozanolixizumab blocks the neonatal Fc receptor, which normally protects IgG antibodies from degradation. Nivolumab is an IgG4 antibody, so its clearance could increase and exposure fall, potentially weakening antitumor effect. The clinical significance is uncertain.
What this interaction means in plain words
Nivolumab and Rozanolixizumab can affect each other. The combination is often manageable, but it may need a change of dose, a change of timing, or extra checks while both are taken.
Nivolumab belongs to Oncology; Rozanolixizumab belongs to Miscellaneous.
Why it happens
Rozanolixizumab blocks FcRn-mediated IgG recycling, which may accelerate catabolism of IgG-based nivolumab.
What to do
Avoid combining where possible, or monitor tumor response closely if rozanolixizumab is necessary. Involve oncology and neurology specialists in weighing alternatives.
What to ask your pharmacist
- Should I take them at different times of day?
- Does the dose of either medicine need to change?
- Is there anything I should avoid, such as alcohol or certain foods, while on both?
Pro+ members
Unlock the full page
Create an account and start a Pro+ trial to unlock the full management advice for Nivolumab and Rozanolixizumab, the additional notes, the evidence detail and the whole-prescription interaction checker.
- Full clinical management advice
- Additional notes
- Evidence detail
- Interaction checker for a whole prescription
Try Pro+ free for 14 days on the web. No card needed.
Other interactions of Nivolumab
- Nivolumab + Thalidomide Major
- Dexamethasone-tobramycin + Nivolumab Moderate
- Dexamethasone + Nivolumab Moderate
- Efgartigimod / hyaluronidase sc + Nivolumab Moderate
- Efgartigimod alfa + Nivolumab Moderate
- Nivolumab + Ponesimod Moderate
Other interactions of Rozanolixizumab
- Rozanolixizumab + Upadacitinib Major
- Abatacept + Rozanolixizumab Moderate
- Adalimumab + Rozanolixizumab Moderate
- Ado-trastuzumab + Rozanolixizumab Moderate
- Basiliximab + Rozanolixizumab Moderate
- Bevacizumab + Rozanolixizumab Moderate
Frequently asked questions
Can I take Nivolumab with Rozanolixizumab?
MediHelp rates the interaction as moderate. Nivolumab and Rozanolixizumab can affect each other. The combination is often manageable, but it may need a change of dose, a change of timing, or extra checks while both are taken. Rozanolixizumab blocks the neonatal Fc receptor, which normally protects IgG antibodies from degradation. Nivolumab is an IgG4 antibody, so its clearance could increase and exposure fall, potentially weakening antitumor effect. The clinical significance is uncertain.
How serious is the interaction between Nivolumab and Rozanolixizumab?
MediHelp rates it moderate, on a four-level scale (minor, moderate, major, contraindicated) based on published labels and references. What to do, in brief: Avoid combining where possible, or monitor tumor response closely if rozanolixizumab is necessary. Involve oncology and neurology specialists in weighing alternatives.
What other medicines interact with Nivolumab?
MediHelp also lists interactions of Nivolumab with, for example, Thalidomide, Dexamethasone-tobramycin, Dexamethasone. The full list is on the Nivolumab page.
Full monographs, dosing and an interaction checker in the MediHelp app
Open the complete reference, check multi-drug interactions and use dosing tools in the MediHelp app.
